CervoMed Inc. filings document a clinical-stage biotechnology issuer focused on neflamapimod and age-related brain disorders. Form 8-K reports include Regulation FD disclosures, press release exhibits, operating and financial results, and updates on clinical studies such as RewinD-LB in dementia with Lewy bodies, pharmacokinetic work, biomarker analyses, and ALS platform inclusion.
Proxy materials describe shareholder voting matters, board and governance practices, executive compensation, equity awards, and related pay-versus-performance disclosures. The filing record also identifies CRVO common stock on the Nasdaq Capital Market and provides capital-structure, business-development, and financial-position disclosures relevant to CervoMed's drug-development model.
CervoMed Inc. files a shelf registration to permit resale by selling stockholders of up to 10,081,131 shares of common stock, consisting of issued shares and shares issuable upon exercise of Pre-Funded Warrants, Series B Warrants and Series C Warrants issued in a June 11, 2026 private placement. The Company states it will not receive proceeds from resale by the selling stockholders but would receive cash proceeds if any Warrants are exercised for cash, and discloses recent financings including a 2,500,000-share Registered Offering that closed June 22, 2026 for gross proceeds of $10.0 million.
CervoMed Inc. Schedule 13G filing reports that CVI Investments, Inc. and Heights Capital Management, Inc. together beneficially hold 750,000 shares of CervoMed common stock, representing 5.5% of the class. The filing references 13,526,233 Shares outstanding as of completion of the offering per the Prospectus Supplement dated June 22, 2026. Heights Capital Management, Inc. is the investment manager to CVI Investments, Inc. and may be deemed to possess voting and dispositive power over the shares; both Reporting Persons disclaim beneficial ownership except for pecuniary interest. The submission is signed by Sarah Travis and includes a Limited Power of Attorney and a Joint Filing Agreement as exhibits.
CervoMed Inc. closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, raising gross proceeds of $10 million. The transaction was priced at-the-market under Nasdaq rules, with H.C. Wainwright & Co. acting as exclusive placement agent.
The company plans to use the net proceeds for working capital and general corporate purposes. The shares were issued under an effective Form S-3 shelf registration statement using a final prospectus supplement and accompanying prospectus filed with the SEC.
CervoMed Inc. is offering 2,500,000 shares of common stock at an offering price of $4.00 per share pursuant to this prospectus supplement. Delivery is expected on or about June 22, 2026, with estimated net proceeds to the company of approximately $9.1 million.
The offering is being conducted on a best-efforts basis with H.C. Wainwright & Co. as exclusive placement agent and assumes sale of all shares. The prospectus supplement notes a public float of $32,126,620 based on 11,026,233 shares outstanding and 7,105,447 shares held by non-affiliates. Recent corporate items include a notice of allowance from the U.S. Patent and Trademark Office dated June 16, 2026 and a closed private placement on June 11, 2026 that generated approximately $10.5 million in gross proceeds.
CervoMed Inc. entered into definitive agreements for a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, for aggregate gross proceeds of $10.0 million. The company plans to use the net proceeds for working capital and general corporate purposes.
H.C. Wainwright & Co. is acting as exclusive placement agent, receiving a 6.0% cash fee, a 1.0% management fee, specified expense reimbursements, and Placement Agent Warrants equal to 6.0% of the shares sold, exercisable at $5.00 per share. CervoMed agreed to a 30‑day lock‑up on most new equity issuances and a six‑month restriction on variable rate transactions, with customary exceptions. The new shares are being issued off an effective Form S‑3 shelf, while the Placement Agent Warrants and any pre‑funded warrants are being issued in a private placement with beneficial ownership limits of 4.99%, adjustable up to 9.99% after notice.
CervoMed Inc. reported that it received a notice of allowance from the United States Patent and Trademark Office for a new patent covering its drug candidate neflamapimod. The patent protects use of neflamapimod to treat dementia with Lewy bodies in patients without substantial Alzheimer’s disease-like tau pathology and is expected to provide intellectual property protection into 2042, strengthening long-term exclusivity for this indication.
Joshua S. Boger filed Amendment No. 2 to his Schedule 13D on CervoMed Inc., reporting beneficial ownership of 2,204,143 shares of common stock, or 19.99% of the outstanding shares, based on 11,026,233 shares of common stock outstanding.
His position includes shares held directly, through the JSB 2021 Trust and ASB 2021 Trust, as well as stock options and a limited amount of warrant shares constrained by a 19.99% maximum ownership limitation. The filing also reflects participation by the JSB 2021 Trust in a June 11, 2026 private placement of 955,414 units, each priced at $3.14 and including common stock plus Series B and Series C warrants.
CervoMed Inc. director-associated trusts participated in a significant private placement. On June 11, 2026, the Joshua S. Boger 2021 Trust purchased 955,414 units at $3.14 per unit in a private placement, each unit consisting of one share of common stock plus one Series B warrant and one Series C warrant.
The Series B warrants have a $3.32 exercise price and expire five years from issuance, while the Series C warrants have a $3.14 exercise price and expire one year from issuance. After these transactions, trusts for which Joshua S. Boger is sole trustee hold 1,600,117 and 195,748 common shares, respectively, though he disclaims beneficial ownership of these securities.
CervoMed Inc. furnished an update that investor presentation materials about its business, clinical studies, development plans and financial position are available on its website under the Investors – Events and Presentations section. The company notes these materials may be used in meetings with investors, analysts and others.
The information is provided under Regulation FD as furnished, not filed, meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other SEC filings unless specifically referenced.
CervoMed Inc. director Frank Zavrl received a grant of stock options as part of his non-employee director compensation. On June 8, 2026, he was awarded options to purchase 8,150 shares of common stock at an exercise price of $2.91 per share under the 2025 Equity Incentive Plan. These options vest monthly in substantially equal 1/12th increments over one year beginning June 30, 2026, contingent on his continued board service. Following this grant, Zavrl holds 8,150 stock options directly.